Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dolphin Neurostim is a private healthcare and medical device company focused on non-invasive pain and stress management using handheld microcurrent neurostimulation devices and associated treatment protocols. The company markets the Dolphin Neurostim device and teaches Microcurrent Point Stimulation (MPS) Therapy, an electrotherapy approach that applies concentrated direct-current micro-impulses to acupuncture, trigger, and neurological points. Its commercial offering spans device sales, practitioner training, online and in-person courses, and protocol-driven applications in pain management, scar release, vagus nerve therapy, and concussion-related care. The company positions its products for use by healthcare professionals as well as certain home users, and highlights published research across pain, stress, scar, and neuromodulation-related use cases. Dolphin Neurostim appears to operate as an active, private, commercial-stage medical device business rather than a drug-development biotech company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dolphin Neurostim.